ES2745539T3 - Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos - Google Patents
Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos Download PDFInfo
- Publication number
- ES2745539T3 ES2745539T3 ES13763620T ES13763620T ES2745539T3 ES 2745539 T3 ES2745539 T3 ES 2745539T3 ES 13763620 T ES13763620 T ES 13763620T ES 13763620 T ES13763620 T ES 13763620T ES 2745539 T3 ES2745539 T3 ES 2745539T3
- Authority
- ES
- Spain
- Prior art keywords
- app
- certain embodiments
- alzheimer
- disease
- galangine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *Oc(cc1O*)cc(OC(C2=CC=CC=CC2)=C2O*)c1C2=O Chemical compound *Oc(cc1O*)cc(OC(C2=CC=CC=CC2)=C2O*)c1C2=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612848P | 2012-03-19 | 2012-03-19 | |
| US201261728688P | 2012-11-20 | 2012-11-20 | |
| PCT/US2013/032481 WO2013142370A1 (en) | 2012-03-19 | 2013-03-15 | APP SPECIFIC BACE INHIBITORS (ASBIs) AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2745539T3 true ES2745539T3 (es) | 2020-03-02 |
Family
ID=49223272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13763620T Active ES2745539T3 (es) | 2012-03-19 | 2013-03-15 | Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | USRE49873E1 (enExample) |
| EP (2) | EP3607946B1 (enExample) |
| JP (2) | JP6482458B2 (enExample) |
| KR (2) | KR102073578B1 (enExample) |
| CN (2) | CN106902108B (enExample) |
| AU (2) | AU2013235422B2 (enExample) |
| CA (1) | CA2867891C (enExample) |
| DK (1) | DK2827711T3 (enExample) |
| ES (1) | ES2745539T3 (enExample) |
| WO (1) | WO2013142370A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2745539T3 (es) * | 2012-03-19 | 2020-03-02 | Buck Inst Res Aging | Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos |
| US10729777B2 (en) | 2012-04-09 | 2020-08-04 | Case Western Reserve University | Compositions and methods for inhibiting the activity of LAR family phosphatases |
| CN104800200B (zh) * | 2014-01-23 | 2019-04-02 | 上海中医药大学 | 高良姜素的医药用途 |
| WO2016072522A1 (ja) * | 2014-11-06 | 2016-05-12 | 国立大学法人 長崎大学 | 新規アルツハイマー病治療薬 |
| AU2016220049C1 (en) | 2015-02-18 | 2021-02-25 | Buck Institute For Research On Aging | Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau |
| CN106474101A (zh) * | 2015-06-17 | 2017-03-08 | 海南医学院 | 高良姜素在治疗糖尿病脑病药物中的应用 |
| KR101716571B1 (ko) * | 2015-06-19 | 2017-03-15 | 단국대학교 천안캠퍼스 산학협력단 | 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물 |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| WO2018073321A1 (en) | 2016-10-18 | 2018-04-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Natural product derivatives for inhibiting cellular necroptosis, ferroptosis and oxytosis |
| KR20200045446A (ko) * | 2017-06-05 | 2020-05-04 | 케이스 웨스턴 리저브 유니버시티 | 알츠하이머병의 치료를 위한 조성물 및 방법 |
| GB2574878A (en) * | 2018-06-22 | 2019-12-25 | Biofilm Ltd | Oral compositions and mucoadhesive thin films formed therefrom |
| JP7589143B2 (ja) | 2018-09-05 | 2024-11-25 | ケース ウエスタン リザーブ ユニバーシティ | 神経可塑性を誘導するための方法および組成物 |
| AU2020395610A1 (en) * | 2019-12-06 | 2022-06-30 | Gretals Australia Pty Ltd | Neurologically active flavonoid compositions and methods of use thereof |
| CN111518793A (zh) * | 2020-05-20 | 2020-08-11 | 谭骏 | 年轻人血源APPα-分泌酶在阿尔茨海默病中的应用 |
| WO2022035758A1 (en) * | 2020-08-12 | 2022-02-17 | The Cleveland Clinic Foundation | Bace1 inhibitor treatment for suppressing cytokine storm |
| CN112730839B (zh) * | 2021-01-20 | 2024-01-30 | 宁波海尔施智造有限公司 | 一种磁微粒化学发光法测定细胞角蛋白19片段含量的试剂盒 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| CH677886A5 (enExample) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| JPH06507782A (ja) | 1990-06-15 | 1994-09-08 | サイオス ノバ インコーポレイテッド | アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物 |
| AU652997B2 (en) | 1991-01-21 | 1994-09-15 | Elan Pharmaceuticals, Inc. | Test and model for alzheimer's disease |
| DE69233109T2 (de) | 1992-01-07 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Transgene tiermodelle fur alzheimer-krankheit |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| FR2730932B1 (fr) | 1995-02-27 | 1997-04-04 | Oreal | Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| JPH11507538A (ja) | 1995-06-07 | 1999-07-06 | アテナ ニューロサイエンシズ インコーポレイティド | β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ |
| FR2742676B1 (fr) | 1995-12-21 | 1998-02-06 | Oreal | Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie |
| JP4431638B2 (ja) * | 1996-01-29 | 2010-03-17 | アメリカ合衆国 | ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途 |
| FR2755854B1 (fr) | 1996-11-15 | 1998-12-24 | Oreal | Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations |
| FR2760970B1 (fr) | 1997-03-18 | 2000-03-10 | Oreal | Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations |
| US6492377B1 (en) * | 1998-06-25 | 2002-12-10 | Boehringer Ingelheim Pharma Kg | Imidazotriazolopyrimidines with adenosine-antagonistic activity |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| ES2318902T3 (es) | 1998-09-24 | 2009-05-01 | PHARMACIA & UPJOHN COMPANY LLC | Secretasa en la enfermedad del alzheimer. |
| FR2787026B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787027B1 (fr) | 1998-12-14 | 2001-01-12 | Oreal | Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787326B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787325B1 (fr) | 1998-12-17 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2787728B1 (fr) | 1998-12-23 | 2001-01-26 | Oreal | Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2787703B1 (fr) | 1998-12-29 | 2001-01-26 | Oreal | Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788007B1 (fr) | 1999-01-05 | 2001-02-09 | Oreal | Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| FR2788449B1 (fr) | 1999-01-14 | 2001-02-16 | Oreal | Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| FR2789076B1 (fr) | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| US7161962B1 (en) | 1999-05-27 | 2007-01-09 | Nuera Communications, Inc. | Method and apparatus for coding modem signals for transmission over voice networks |
| US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| FR2811564B1 (fr) | 2000-07-13 | 2002-12-27 | Oreal | Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique |
| WO2002055562A2 (en) | 2001-01-11 | 2002-07-18 | Eastman Chem Co | Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials |
| FR2819427B1 (fr) | 2001-01-18 | 2003-04-11 | Oreal | Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique |
| EP2545937A1 (en) | 2001-06-05 | 2013-01-16 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
| UY26816A1 (es) * | 2001-07-04 | 2003-04-30 | Horacio Heinzen | Una preparación liposomal de achyrocline satureioides ("marcela"), flavonoides y derivados semisintéticos, para la protección del tejido cerebral frente al dano isquémico- vascular y neurodegenerativo. |
| CA2703698C (en) * | 2002-04-30 | 2016-11-22 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| US7476393B2 (en) | 2002-11-29 | 2009-01-13 | L'oreal | Process for the preparation of a cationic nanoemulsion, and cosmetic composition |
| CA2534950A1 (en) | 2003-08-08 | 2005-02-24 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| CN1863770B (zh) | 2003-08-08 | 2011-05-25 | 先灵公司 | 具有杂环取代基的环胺base-1抑制剂 |
| JP2005104850A (ja) | 2003-09-26 | 2005-04-21 | Kanazawa Univ Tlo Inc | アルツハイマー病の治療薬および予防薬 |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| CA2548388A1 (en) | 2003-12-15 | 2005-06-30 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7468402B2 (en) | 2004-03-17 | 2008-12-23 | Baker Hughes Incorporated | Polymeric nanoemulsion as drag reducer for multiphase flow |
| CA2579724A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| CA2578600A1 (en) | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase |
| KR100610562B1 (ko) * | 2004-06-28 | 2006-08-08 | 재단법인서울대학교산학협력재단 | 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물 |
| JP2008507538A (ja) | 2004-07-22 | 2008-03-13 | シェーリング コーポレイション | 置換アミドβセクレターゼインヒビター |
| CA2575340A1 (en) | 2004-07-28 | 2006-02-09 | Schering Corporation | Macrocyclic beta-secretase inhibitors |
| CN100441200C (zh) * | 2004-11-26 | 2008-12-10 | 谢德隆 | 石杉碱甲、乙复合成分的蛇足石杉提取物及其制备方法 |
| CA2609562A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
| US7759353B2 (en) | 2005-06-14 | 2010-07-20 | Schering Corporation | Substituted spiro iminopyrimidinones as aspartyl protease inhibitors, compositions, and methods of treatment |
| EP1896406A2 (en) | 2005-06-14 | 2008-03-12 | Shering Corporation | The preparation and use of compounds as protease inhibitors |
| ATE489370T1 (de) | 2005-06-14 | 2010-12-15 | Schering Corp | Herstellung und verwendung von verbindungen als aspartylproteasehemmer |
| US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| ATE482214T1 (de) | 2005-06-14 | 2010-10-15 | Schering Corp | Aspartylproteasehemmer |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| BRPI0613578A2 (pt) | 2005-06-30 | 2012-01-17 | Wyeth Corp | composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica |
| TW200730523A (en) | 2005-07-29 | 2007-08-16 | Wyeth Corp | Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation |
| RU2008106936A (ru) | 2005-09-26 | 2009-11-10 | Вайет (Us) | Соединения амино-5-[4-(дифторметокси)фенил]-5-фенилимидазолона для ингибирования бета-секретазы |
| CN101296926A (zh) | 2005-10-27 | 2008-10-29 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| CN101351460A (zh) | 2005-10-31 | 2009-01-21 | 先灵公司 | 天冬氨酰蛋白酶抑制剂 |
| JP2009532464A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ・アクチエボラーグ | ２−アミノピリミジン−４−オン及びＡβ−関連の病理を治療又は予防するためのその使用 |
| CA2653650A1 (en) | 2006-06-12 | 2007-12-21 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200815443A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds I |
| TW200815449A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds II |
| TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
| TW200808796A (en) | 2006-06-14 | 2008-02-16 | Astrazeneca Ab | New compounds III |
| TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
| WO2008011538A2 (en) * | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
| MX2009006228A (es) | 2006-12-12 | 2009-06-22 | Schering Corp | Inhibidores de aspartil proteasa. |
| CN101631779A (zh) | 2006-12-12 | 2010-01-20 | 先灵公司 | 含有三环系统的天冬氨酰蛋白酶抑制剂 |
| US20090041201A1 (en) | 2007-08-06 | 2009-02-12 | Carestream Health, Inc. | Alignment apparatus for imaging system |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| AP2011005707A0 (en) | 2008-11-11 | 2011-06-30 | Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd | Inclusion complexes of pinocembrin with cyclodextrin or its derivatives. |
| US8466195B2 (en) * | 2009-03-13 | 2013-06-18 | Salk Institute For Biological Studies | Methods and compositions for treating complications of diabetes and vascular diseases using flavones |
| CN101543505A (zh) | 2009-04-29 | 2009-09-30 | 香港科技大学 | 一种预防和治疗阿尔茨海默氏症的药物及其制备方法 |
| CN103200949B (zh) * | 2010-08-10 | 2016-10-12 | 香港科技大学 | 用于治疗神经变性疾病或神经病理性病症的组合物 |
| ES2745539T3 (es) | 2012-03-19 | 2020-03-02 | Buck Inst Res Aging | Inhibidores de BACE específicos de APP (ASBI) y uso de los mismos |
-
2013
- 2013-03-15 ES ES13763620T patent/ES2745539T3/es active Active
- 2013-03-15 KR KR1020147029321A patent/KR102073578B1/ko active Active
- 2013-03-15 CN CN201710107804.5A patent/CN106902108B/zh active Active
- 2013-03-15 JP JP2015501819A patent/JP6482458B2/ja active Active
- 2013-03-15 CN CN201380023606.0A patent/CN104270945B/zh active Active
- 2013-03-15 US US17/382,969 patent/USRE49873E1/en active Active
- 2013-03-15 WO PCT/US2013/032481 patent/WO2013142370A1/en not_active Ceased
- 2013-03-15 US US14/384,641 patent/US10357508B2/en not_active Ceased
- 2013-03-15 AU AU2013235422A patent/AU2013235422B2/en active Active
- 2013-03-15 KR KR1020207002843A patent/KR102160388B1/ko active Active
- 2013-03-15 DK DK13763620.5T patent/DK2827711T3/da active
- 2013-03-15 EP EP19180690.0A patent/EP3607946B1/en active Active
- 2013-03-15 CA CA2867891A patent/CA2867891C/en active Active
- 2013-03-15 EP EP13763620.5A patent/EP2827711B1/en active Active
-
2017
- 2017-03-08 AU AU2017201599A patent/AU2017201599B2/en active Active
- 2017-12-05 JP JP2017233222A patent/JP2018035197A/ja active Pending
-
2019
- 2019-06-06 US US16/433,879 patent/US10835546B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10357508B2 (en) | 2019-07-23 |
| EP2827711B1 (en) | 2019-06-19 |
| JP6482458B2 (ja) | 2019-03-13 |
| KR20150002681A (ko) | 2015-01-07 |
| CA2867891C (en) | 2021-09-14 |
| EP3607946A1 (en) | 2020-02-12 |
| CN106902108B (zh) | 2020-07-21 |
| KR102073578B1 (ko) | 2020-02-05 |
| CN106902108A (zh) | 2017-06-30 |
| JP2018035197A (ja) | 2018-03-08 |
| JP2015510941A (ja) | 2015-04-13 |
| US20190298748A1 (en) | 2019-10-03 |
| AU2017201599A1 (en) | 2017-03-30 |
| AU2013235422B2 (en) | 2016-12-15 |
| CN104270945B (zh) | 2017-03-29 |
| AU2013235422A1 (en) | 2014-10-02 |
| CN104270945A (zh) | 2015-01-07 |
| USRE49873E1 (en) | 2024-03-19 |
| EP2827711A4 (en) | 2016-03-23 |
| US10835546B2 (en) | 2020-11-17 |
| KR102160388B1 (ko) | 2020-09-28 |
| US20150306122A1 (en) | 2015-10-29 |
| WO2013142370A1 (en) | 2013-09-26 |
| EP3607946B1 (en) | 2023-02-22 |
| AU2017201599B2 (en) | 2018-11-08 |
| DK2827711T3 (da) | 2019-09-23 |
| CA2867891A1 (en) | 2013-09-26 |
| EP2827711A1 (en) | 2015-01-28 |
| KR20200013807A (ko) | 2020-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10835546B2 (en) | App specific BACE inhibitors (ASBIs) and uses thereof | |
| ES2975235T3 (es) | Hidantoínas que modulan el procesamiento de APP mediado por BACE | |
| JP2023153783A (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| ES2705027T3 (es) | Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados | |
| KR20190039226A (ko) | 리소좀 축적 질환과 관련된 약제 조성물 및 용도 | |
| CN107709326B (zh) | 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶 | |
| US20220041553A1 (en) | Apoe4-targeted theraputics that increase sirt1 |